Article
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
Clinica chimica acta; international journal of clinical chemistry - 1 Feb 2009
Ruaño Gualberto, Bernene James, Windemuth Andreas, Bower Bruce, Wencker Detlef, Seip Richard L, Kocherla Mohan, Holford Theodore R, Petit William A, Hanks Steven
Abstract excerpt
BACKGROUND: The thiazolidinediones (TZDs) improve tissue sensitivity to insulin in patients with type II diabetes, resulting in reduced levels of fasting blood glucose and glycated hemoglobin. However, TZDs unpredictably demonstrate adverse effects of increased body weight, fluid retention, and edema. The balance of efficacy and safety of TZD varies widely from patient to patient. Genetic variability may reveal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
